Printer Friendly

Novartis and IBM Watson Health collaborating on outcomes-based care in advanced breast cancer.

M2 EQUITYBITES-June 7, 2017-Novartis and IBM Watson Health collaborating on outcomes-based care in advanced breast cancer

(C)2017 M2 COMMUNICATIONS http://www.m2.com

Novartis (VTX: NOVN) has joined forces with IBM Watson Health with the aim of tackling advanced breast cancer with an outcome-based initiative, Pharmafile reported on Wednesday.

The two companies will work together to explore the development of a cognitive solution that uses real-world data and advanced analytical techniques to provide better insights on the expected outcomes of breast cancer treatment options.

The collaboration will bring together Novartis' expertise in breast cancer with IBM Watson Health's skill in data analytics and machine learning.

Breast cancer is a priority oncology focus area for Novartis, with the company working on breast cancer treatments for over 25 years. It now has four marketed breast cancer drugs, Kisqali (ribociclib) which is only commercially available in the US, Afinitor (everolimus), Tykerb/Tyverb (lapatinib) and Femara (letrozole). The company also has the largest number of breast cancer compounds in development, including BYL719 (alpelisib), an alpha-specific PI3K inhibitor; LSZ102, an oral SERD; LJM716, a fully human, anti-HER3 IgG1 antibody; and MCS110, a colony-stimulating factor 1 (CSF1) inhibitor.

Novartis Oncology CEO, Bruno Strigini, said the aim of the collaboration is "to identify solutions that may help physicians better understand which therapy may be best for which patients or advise clinical practice guidelines, with the goal of improving patient outcomes and experiences."

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jun 7, 2017
Words:247
Previous Article:AstraZeneca sells migraine treatment to GrA1/4nenthal.
Next Article:Ixia, Arrow Electronics include EMEA in growing relationship.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters